Tender Number 1

This tender, designated as Tender Number 1 (sub-contract), pertains to the supply of specific pharmaceutical products. The primary focus is on the drug identified by ATC Code B02BD13, with the generic name Coagulation factor X. The specified dosage form is an injection, and the strength ranges from 250 to 500 IU, with a unit value of 250 IU. The estimated quantity required is 400 units. Each tender number is treated as an independent sub-contract and will be awarded separately. Suppliers have the flexibility to bid on one, several, or all available tender numbers, and contract awards will be made on an individual basis for each tender number. Consequently, a single supplier may be awarded one, multiple, or all of the sub-contracts. Interested parties are directed to the tender conditions for detailed information regarding the submission of bids for individual tender numbers. The quantity indicated as 'quantity in units' represents an estimated consumption; however, the actual consumption may vary significantly. Suppliers must account for this variability, as the pharmaceuticals are intended for patient treatment in public hospitals, where patient needs dictate actual usage. Further details are available in the tender conditions and the framework agreement.

This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals. Located in Denmark, Europe, this opportunity is open to firms and consortiums, with an estimated budget of DKK 20.8 million.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.